Filing Flows › TG Therapeutics (TGTX) › Q3 2025
TG Therapeutics (TGTX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
TG Therapeutics (TGTX) reported revenue of $162M for the third quarter 2025 (Q3 2025), +93% from a year earlier and +15% from the quarter before. Operating margin was 18.2%, net earnings $391M (241.7% of revenue).
TG Therapeutics, Q3 2025: revenue $162M (+93% year over year), operating margin 18.2%, net earnings $391M, operating cash flow −$23.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $162M | +15% | +93% |
| Operating profit | $29.4M | -16% | +136% |
| Net earnings | $391M | 14× | 101× |
| Operating cash flow | −$23.2M | -411% | — |
What changed
Revenue was $161.7M in Q3 2025, up 93% year over year and up 15% from the previous quarter. Product was the largest line at 99% of revenue. Product added $76.0M year over year (up 91%), 98% of the total change.
Operating profit was $29.4M, a 18.2% margin (up 3.3 points year over year). Of the extra revenue versus a year earlier, 22% reached operating profit, above the 15% margin then. Total costs grew 85% against revenue growth of 93%. The fastest-growing cost line was Cost of revenue (+201%). Net earnings were $390.9M, up 9975% year over year. The tax line was a benefit of $365.0M on pre-tax earnings of $25.9M.
Operating cash flow was −$23.2M. Non-cash charges added back $17K of depreciation and amortization and $17.7M of share-based compensation. Working capital and other items used $431.8M. Capital expenditures of $80K exceeded it, leaving free cash flow of −$23.2M.
Questions
What was TG Therapeutics' revenue in the third quarter 2025?
TG Therapeutics (TGTX) reported revenue of $162M for the third quarter 2025 (Q3 2025), +93% from a year earlier and +15% from the quarter before.
Was TG Therapeutics profitable in the third quarter 2025?
Operating profit was $29.4M (18.2% of revenue) and net earnings $391M.
Source: TG Therapeutics 10-Q on SEC EDGAR.